文献速递炎症性肠病

美国炎症性肠病经济负担、财务困扰与财务毒性的叙述性综述

A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States.
PubMed 文献 · Am J Gastroenterol · 2023-05-25

该叙述性综述检索2002年至2022年美国研究,纳入18篇文献、638664例9至93岁炎症性肠病患者,总结患者层面直接/间接费用、财务困扰与财务毒性。患者年直接费用估计为7824至41829美元,财务困扰普遍存在,与教育程度低、家庭收入低、公共保险、合并症、疾病严重程度及食物不安全相关;财务毒性尚缺乏充分描述。

要点

  • 患者年直接费用估计为7824至41829美元,克罗恩病费用高于溃疡性结肠炎。
  • 财务困扰普遍存在,与低教育水平、低收入、公共保险、合并症、疾病严重程度和食物不安全相关。
  • 财务困扰程度越高,医疗延迟、因费用导致的用药不依从及健康相关生活质量降低越明显。

核心结论

  • 财务困扰在炎症性肠病患者中普遍存在;财务毒性尚缺乏充分描述。
  • 相关定义与测量方法差异很大;需要更好地量化患者层面费用及相关影响以确定干预途径。

研究设计与样本

  • 叙述性综述,检索2002年至2022年美国研究,聚焦炎症性肠病患者直接/间接费用、财务困扰与财务毒性。
  • 筛查2586篇摘要,最终纳入18篇文章,涵盖638664例9至93岁炎症性肠病患者。

主要发现

  • 患者年直接费用估计为7824至41829美元。
  • 门诊费用占直接费用的19%至45%,住院费用占27%至36%,药房费用占7%至51%。
  • 克罗恩病费用高于溃疡性结肠炎;间接费用估计差异很大,出勤主义(presenteeism)占间接费用的大部分。
  • 严重和活动性疾病与更高的直接和间接费用相关。
  • 财务困扰普遍存在,相关因素包括教育程度较低、家庭收入较低、公共保险、合并症、炎症性肠病严重程度和食物不安全;财务困扰程度越高与医疗延迟、因费用导致的用药不依从及健康相关生活质量较低相关。

局限性

  • 财务毒性尚缺乏充分描述。
  • 相关定义与测量方法差异很大。
  • 需要更好地量化患者层面费用及相关影响以确定干预途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Inflammatory bowel diseases (IBD) affect >3 million Americans and are associated with tremendous economic burden. Direct patient-level financial impacts, financial distress, and financial toxicity are less well understood. We aimed to summarize the literature on patient-level financial burden, distress, and toxicity associated with IBD in the United States. METHODS: We conducted a literature search of US studies from 2002 to 2022 focused on direct/indirect costs, financial distress, and toxicity for patients with IBD. We abstracted study objectives, design, population characteristics, setting, and results. RESULTS: Of 2,586 abstracts screened, 18 articles were included. The studies comprised 638,664 patients with IBD from ages 9 to 93 years. Estimates for direct annual costs incurred by patients ranged from $7,824 to $41,829. Outpatient costs ranged from 19% to 45% of direct costs, inpatient costs ranged from 27% to 36%, and pharmacy costs ranged from 7% to 51% of costs. Crohn's disease was associated with higher costs than ulcerative colitis. Estimates for indirect costs varied widely; presenteeism accounted for most indirect costs. Severe and active disease was associated with greater direct and indirect costs. Financial distress was highly prevalent; associated factors included lower education level, lower household income, public insurance, comorbid illnesses, severity of IBD, and food insecurity. Higher degrees of financial distress were associated with greater delays in medical care, cost-related medication nonadherence, and lower health-related quality of life. DISCUSSION: Financial distress is prevalent among patients with IBD; financial toxicity is not well characterized. Definitions and measures varied widely. Better quantification of patient-level costs and associated impacts is needed to determine avenues for intervention.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kahn-Boesel O, Cautha S, Ufere NN, et al. A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States. Am J Gastroenterol. 2023. PMID: 37224301. doi:10.14309/ajg.0000000000002345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。